http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114870010-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a28e711b9cffb2aa01a4cba79ef5700c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate | 2022-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d17be8e7a809a83298eddaff8a3e87f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c13ae60f881e2606a544ded745108ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e27b8d0dbf3da6de283388796de35183 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c0a2a37f9de6ef00ed5eef794146693 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66269db6cdcba8d701830fb1dd50f762 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5e05f16a511e652a67e8199c53371d0 |
| publicationDate | 2022-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114870010-A |
| titleOfInvention | Application of PDL1 antibody in retinal nerve injury and neurodegenerative eye disease |
| abstract | The present invention relates to the application of anti-PDL1 antibody for treating retinal nerve damage and neurodegenerative eye disease. The present invention constructs 3 kinds of retinal nerve damage and neurodegenerative eye disease mice. It is confirmed by ERG, OCT, H&E and other experiments that intravitreal injection of anti-PDL1 antibody can significantly reduce retinal nerve cell damage in diseased mice, protect visual function, and delay Thinning of the retina. In vivo phagocytosis experiments confirmed that anti-PDL1 antibody can enhance the phagocytic function of retinal microglia, promote the phagocytosis of apoptotic neurons, reduce retinal inflammation, and promote the recovery of visual function. The invention provides experimental basis and theoretical basis for the anti-PDL1 antibody to treat retinal nerve damage and neurodegenerative ophthalmopathy, and the anti-PDL1 antibody will have a clear transformation and application prospect in the preparation of pharmaceutical preparations for the treatment of retinal nerve damage and neurodegenerative ophthalmopathy. |
| priorityDate | 2022-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 174.